Diabetic Cardiomyopathy, Causes and Effects

Overview

Journal Rev Endocr Metab Disord

Publisher Springer

Specialty Endocrinology

Date 2010 Feb 25

PMID 20180026

Citations 340

Authors

Sihem Boudina

Evan Dale Abel

Affiliations

Soon will be listed here.

Abstract

Diabetes is associated with increased incidence of heart failure even after controlling for coronary artery disease and hypertension. Thus, as diabetic cardiomyopathy has become an increasingly recognized entity among clinicians, a better understanding of its pathophysiology is necessary for early diagnosis and the development of treatment strategies for diabetes-associated cardiovascular dysfunction. We will review recent basic and clinical research into the manifestations and the pathophysiological mechanisms of diabetic cardiomyopathy. The discussion will be focused on the structural, functional and metabolic changes that occur in the myocardium in diabetes and how these changes may contribute to the development of diabetic cardiomyopathy in affected humans and relevant animal models.

Citing Articles

The Influence of Interatrial Conduction Disorders on Atrial Mechanical Function - Atrial Strain and Pulmonary Veins Reversal Flow in Patients with COVID-19.

Zawadzki J, Gajek J, Zawadzki G, Slawuta A, Kudlinski B Rev Cardiovasc Med. 2025; 26(2):25273.

PMID: 40026521 PMC: 11868908. DOI: 10.31083/RCM25273.

The mTOR Signaling Pathway: Key Regulator and Therapeutic Target for Heart Disease.

Wang J, Huang Y, Wang Z, Liu J, Liu Z, Yang J Biomedicines. 2025; 13(2).

PMID: 40002810 PMC: 11853667. DOI: 10.3390/biomedicines13020397.

Supplementation with aspalathin and sulforaphane protects cultured cardiac cells against dyslipidemia-associated oxidative damage.

Mthembu S, Mazibuko-Mbeje S, Silvestri S, Orlando P, Nkambule B, Muller C Metabol Open. 2025; 25:100346.

PMID: 39882383 PMC: 11774938. DOI: 10.1016/j.metop.2025.100346.

Sodium-dependent glucose transporter 2 inhibitors improve heart function in patients with type 2 diabetes and heart failure.

Zhang Y, Liu Y, Yang W World J Cardiol. 2025; 17(1):100886.

PMID: 39866214 PMC: 11755127. DOI: 10.4330/wjc.v17.i1.100886.

Alterations in cardiac function correlate with a disruption in fatty acid metabolism in a mouse model of SMA.

Nair N, Kline R, Boyd I, Anikumar M, Thomson A, Lamont D Hum Mol Genet. 2025; 34(6):547-562.

PMID: 39810393 PMC: 11891873. DOI: 10.1093/hmg/ddaf006.

References

Ihm S, Youn H, Shin D, Jang S, Park C, Kim P . Serum carboxy-terminal propeptide of type I procollagen (PIP) is a marker of diastolic dysfunction in patients with early type 2 diabetes mellitus. Int J Cardiol. 2007; 122(3):e36-8. DOI: 10.1016/j.ijcard.2007.07.057. View

Abe T, Ohga Y, Tabayashi N, Kobayashi S, Sakata S, Misawa H . Left ventricular diastolic dysfunction in type 2 diabetes mellitus model rats. Am J Physiol Heart Circ Physiol. 2001; 282(1):H138-48. DOI: 10.1152/ajpheart.2002.282.1.H138. View

Rerkpattanapipat P, DAgostino Jr R, Link K, Shahar E, Lima J, Bluemke D . Location of arterial stiffening differs in those with impaired fasting glucose versus diabetes: implications for left ventricular hypertrophy from the Multi-Ethnic Study of Atherosclerosis. Diabetes. 2009; 58(4):946-53. PMC: 2661581. DOI: 10.2337/db08-1192. View

Bugger H, Abel E . Rodent models of diabetic cardiomyopathy. Dis Model Mech. 2009; 2(9-10):454-66. DOI: 10.1242/dmm.001941. View

Diamant M, Lamb H, Groeneveld Y, Endert E, Smit J, Bax J . Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol. 2003; 42(2):328-35. DOI: 10.1016/s0735-1097(03)00625-9. View

McQueen A, Zhang D, Hu P, Swenson L, Yang Y, Zaha V . Contractile dysfunction in hypertrophied hearts with deficient insulin receptor signaling: possible role of reduced capillary density. J Mol Cell Cardiol. 2005; 39(6):882-92. DOI: 10.1016/j.yjmcc.2005.07.017. View

Scognamiglio R, Avogaro A, Casara D, Crepaldi C, Marin M, Palisi M . Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1998; 31(2):404-12. DOI: 10.1016/s0735-1097(97)00516-0. View

Shimizu M, Umeda K, Sugihara N, YOSHIO H, Ino H, Takeda R . Collagen remodelling in myocardia of patients with diabetes. J Clin Pathol. 1993; 46(1):32-6. PMC: 501107. DOI: 10.1136/jcp.46.1.32. View

Wende A, Abel E . Lipotoxicity in the heart. Biochim Biophys Acta. 2009; 1801(3):311-9. PMC: 2823976. DOI: 10.1016/j.bbalip.2009.09.023. View

10.

Barouch L, Berkowitz D, Harrison R, ODonnell C, Hare J . Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation. 2003; 108(6):754-9. DOI: 10.1161/01.CIR.0000083716.82622.FD. View

11.

Joshi D, Gupta R, Dubey A, Shiwalkar A, Pathak P, Gupta R . TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes. J Cardiovasc Pharmacol. 2009; 54(1):72-81. DOI: 10.1097/FJC.0b013e3181ac3a34. View

12.

Park T, Hu Y, Noh H, Drosatos K, Okajima K, Buchanan J . Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res. 2008; 49(10):2101-12. PMC: 2533410. DOI: 10.1194/jlr.M800147-JLR200. View

13.

Boudina S, Abel E . Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiology (Bethesda). 2006; 21:250-8. DOI: 10.1152/physiol.00008.2006. View

14.

Aasum E, Belke D, Severson D, Riemersma R, Cooper M, Andreassen M . Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am J Physiol Heart Circ Physiol. 2002; 283(3):H949-57. DOI: 10.1152/ajpheart.00226.2001. View

15.

Rijzewijk L, van der Meer R, Lamb H, W A M de Jong H, Lubberink M, Romijn J . Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol. 2009; 54(16):1524-32. DOI: 10.1016/j.jacc.2009.04.074. View

16.

Boudina S, Sena S, Theobald H, Sheng X, Wright J, Hu X . Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes. 2007; 56(10):2457-66. DOI: 10.2337/db07-0481. View

17.

Stolen T, Hoydal M, Kemi O, Catalucci D, Ceci M, Aasum E . Interval training normalizes cardiomyocyte function, diastolic Ca2+ control, and SR Ca2+ release synchronicity in a mouse model of diabetic cardiomyopathy. Circ Res. 2009; 105(6):527-36. DOI: 10.1161/CIRCRESAHA.109.199810. View

18.

Boudina S, Sena S, ONeill B, Tathireddy P, Young M, Abel E . Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation. 2005; 112(17):2686-95. DOI: 10.1161/CIRCULATIONAHA.105.554360. View

19.

Devereux R, Roman M, Paranicas M, OGrady M, Lee E, Welty T . Impact of diabetes on cardiac structure and function: the strong heart study. Circulation. 2000; 101(19):2271-6. DOI: 10.1161/01.cir.101.19.2271. View

20.

Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A . Myocardial cell death in human diabetes. Circ Res. 2000; 87(12):1123-32. DOI: 10.1161/01.res.87.12.1123. View